Treatment of Acute Stroke with Recombinant Tissue Plasminogen Activator and Abciximab
Open Access
- 1 December 2003
- journal article
- Published by Wiley in Academic Emergency Medicine
- Vol. 10 (12) , 1396-1399
- https://doi.org/10.1197/s1069-6563(03)00543-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Adjuvant Treatment With a Glycoprotein IIb/IIIa Receptor Inhibitor Increases the Therapeutic Window for Low-Dose Tissue Plasminogen Activator Administration in a Rat Model of Embolic StrokeCirculation, 2003
- Matrix Metalloproteinase Inhibition Prevents Oxidative Stress-Associated Blood–Brain Barrier Disruption after Transient Focal Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 2001
- Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusionBrain Research, 2001
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trialThe Lancet, 2001
- Hemorrhagic Transformation of Ischemic Brain TissueStroke, 2001
- Anti-GPIIb/IIIa Drugs: Current Strategies and Future DirectionsThrombosis and Haemostasis, 2001
- Trial of Abciximab With and Without Low-Dose Reteplase for Acute Myocardial InfarctionCirculation, 2000
- Abciximab in Acute Ischemic StrokeStroke, 2000
- Binding of Abciximab to αVβ3 and Activated αMβ2 Receptors: With a Review of Platelet-Leukocyte InteractionsThrombosis and Haemostasis, 1999
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995